Semiflexible Immunobrushes Induce Enhanced T Cell Activation and Expansion
Source abstract
Abstract
A variety of bioactive materials developed to expand T cells for adoptive transfer into cancer patients are currently evaluated in the clinic. In most cases, T cell activating biomolecules are attached to rigid surfaces or matrices and form a static interface between materials and the signaling receptors on the T cells. We hypothesized that a T cell activating polymer brush interface might better mimic the cell surface of a natural antigen-presenting cell, facilitating receptor movement and concomitant advantageous mechanical forces to provide enhanced T cell activating capacities. Here, as a proof of concept, we synthesized semiflexible polyisocyanopeptide (PIC) polymer-based immunobrushes equipped with T cell activating agonistic anti-CD3 (αCD3) and αCD28 antibodies placed on magnetic microbeads. We demonstrated enhanced efficiency of ex vivo expansion of activated primary human T cells even at very low numbers of stimulating antibodies compared to rigid beads. Importantly, the immunobrush architecture appeared crucial for this improved T cell activating capacity. Immunobrushes outperform current benchmarks by producing higher numbers of T cells exhibiting a combination of beneficial phenotypic characteristics, such as reduced exhaustion marker expression, high cytokine production, and robust expression of cytotoxic hallmarks. This study indicates that semiflexible immunobrushes have great potential in making T cell-based immunotherapies more effective.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CAR-T cell therapy research · Immunotherapy and Immune Responses · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 26, 6525 GA Nijmegen, Netherlands
Division of Immunotherapy, Oncode Institute, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
Institute for Chemical Immunology, 6525 GA Nijmegen, Netherlands
Funding
H2020 Research Infrastructures · FP7 Ideas: European Research Council · Nederlandse Organisatie voor Wetenschappelijk Onderzoek · Oncode Institute
References (68)
Show source-provided references
1. 10.1038/ni1102-99110.1038/ni1102-991 ↗
2. 10.1016/j.it.2015.02.00810.1016/j.it.2015.02.008 ↗
3. 10.1016/s0065-2776(06)90002-910.1016/s0065-2776(06)90002-9 ↗
4. Anusha A. · J. Pharm. Sci. Res. · 2017 · 9 · 662
5. 10.1038/nri319110.1038/nri3191 ↗
6. 10.1200/JCO.2012.46.644110.1200/JCO.2012.46.6441 ↗
7. 10.1158/1078-0432.CCR-11-011610.1158/1078-0432.CCR-11-0116 ↗
8. 10.1007/s00262-014-1580-510.1007/s00262-014-1580-5 ↗
9. 10.1172/JCI3144610.1172/JCI31446 ↗
10. 10.1126/scitranslmed.aaa364310.1126/scitranslmed.aaa3643 ↗
11. 10.1016/j.tibtech.2014.06.00710.1016/j.tibtech.2014.06.007 ↗
12. 10.1146/annurev.immunol.021908.13270610.1146/annurev.immunol.021908.132706 ↗
13. 10.1016/j.smim.2009.02.00510.1016/j.smim.2009.02.005 ↗
14. 10.1111/j.1600-065X.2009.00784.x10.1111/j.1600-065X.2009.00784.x ↗
15. 10.1101/cshperspect.a01878810.1101/cshperspect.a018788 ↗
16. Neal L. R. · J. Immunol. Res. Ther. · 2017 · 2 · 68
17. 10.1186/1479-5876-8-10410.1186/1479-5876-8-104 ↗
18. Mescher M. F. · J. Immunol. · 1992 · 149 · 240210.4049/jimmunol.149.7.2402 ↗
19. 10.1021/acs.nanolett.7b0373410.1021/acs.nanolett.7b03734 ↗
20. 10.1038/cti.2014.3110.1038/cti.2014.31 ↗
21. 10.1016/S0022-1759(03)00010-310.1016/S0022-1759(03)00010-3 ↗
22. 10.1016/j.intimp.2012.10.02310.1016/j.intimp.2012.10.023 ↗
23. 10.3109/14653249.2011.56329110.3109/14653249.2011.563291 ↗
24. 10.1200/JCO.2014.58.909310.1200/JCO.2014.58.9093 ↗
25. 10.1038/icb.2016.12810.1038/icb.2016.128 ↗
26. 10.3389/fimmu.2016.0034510.3389/fimmu.2016.00345 ↗
27. 10.1186/1479-5876-3-1710.1186/1479-5876-3-17 ↗
28. 10.1111/imr.1213210.1111/imr.12132 ↗
29. 10.1200/JCO.1989.7.2.25010.1200/JCO.1989.7.2.250 ↗
30. 10.1093/jnci/81.22.170910.1093/jnci/81.22.1709 ↗
31. 10.1038/nbt.404710.1038/nbt.4047 ↗
32. 10.1073/pnas.190698611610.1073/pnas.1906986116 ↗
33. 10.1517/14712598.6.3.21510.1517/14712598.6.3.215 ↗
34. 10.1182/blood-2014-01-55217410.1182/blood-2014-01-552174 ↗
35. 10.1016/j.omtm.2017.11.00110.1016/j.omtm.2017.11.001 ↗
36. 10.1016/j.jim.2010.02.00410.1016/j.jim.2010.02.004 ↗
37. 10.1039/c3sc51399h10.1039/c3sc51399h ↗
38. 10.1021/acsomega.6b0043610.1021/acsomega.6b00436 ↗
39. 10.1002/adtp.20180002110.1002/adtp.201800021 ↗
40. 10.1021/cb500455g10.1021/cb500455g ↗
41. 10.1021/acs.biomac.9b0038510.1021/acs.biomac.9b00385 ↗
42. 10.1007/s41061-016-0016-410.1007/s41061-016-0016-4 ↗
43. 10.1021/acs.bioconjchem.7b0039810.1021/acs.bioconjchem.7b00398 ↗
44. 10.1016/j.immuni.2008.08.01110.1016/j.immuni.2008.08.011 ↗
45. Yokosuka T. · Curr. Top. Microbiol. Immunol. · 2010 · 340 · 81
46. 10.1073/pnas.160743611310.1073/pnas.1607436113 ↗
47. 10.1158/2326-6066.CIR-14-016110.1158/2326-6066.CIR-14-0161 ↗
48. 10.1097/00002371-200409000-0001010.1097/00002371-200409000-00010 ↗
49. 10.1021/nl402262310.1021/nl4022623 ↗
50. 10.1007/s00262-013-1459-x10.1007/s00262-013-1459-x ↗
51. 10.1002/eji.20134375110.1002/eji.201343751 ↗
52. 10.1016/j.smim.2016.02.00110.1016/j.smim.2016.02.001 ↗
53. 10.1038/nri386210.1038/nri3862 ↗
54. 10.1074/jbc.M111.27632910.1074/jbc.M111.276329 ↗
55. 10.1038/mt.2008.1110.1038/mt.2008.11 ↗
56. 10.1016/j.biomaterials.2013.09.05010.1016/j.biomaterials.2013.09.050 ↗
57. 10.1002/smll.20140236910.1002/smll.201402369 ↗
58. 10.1038/nnano.2014.15410.1038/nnano.2014.154 ↗
59. 10.1111/j.1365-2567.2011.03458.x10.1111/j.1365-2567.2011.03458.x ↗
60. 10.3389/fimmu.2016.0025510.3389/fimmu.2016.00255 ↗
61. 10.1016/j.coi.2006.03.01410.1016/j.coi.2006.03.014 ↗
62. 10.7554/eLife.2319010.7554/eLife.23190 ↗
63. 10.4049/jimmunol.110275710.4049/jimmunol.1102757 ↗
64. 10.1021/acs.nanolett.6b0407110.1021/acs.nanolett.6b04071 ↗
65. 10.1021/acs.nanolett.9b0225210.1021/acs.nanolett.9b02252 ↗
66. 10.1021/nl403252x10.1021/nl403252x ↗
67. 10.1016/j.bbamcr.2014.09.00110.1016/j.bbamcr.2014.09.001 ↗
68. 10.1016/j.immuni.2013.08.03610.1016/j.immuni.2013.08.036 ↗